In-Vivo Toxicology Testing Industry Report by Regional Category Spend, Price Analysis, Key Demand and Price Indicators, and Best Buying Practices

The global In-Vivo Toxicology Testing market reached a value of about USD 8.6 billion in 2021. The industry is projected to grow at a CAGR of around 9.5% in the forecast period of 2022-2027 to reach a value of about USD 14.82 billion by 2027.

The global In-Vivo Toxicology Testing industry report gives a comprehensive analysis of the industry, including key segments, trends, drivers, restraints, the competitive landscape, and other essential market aspects. The demand for toxicology testing to understand the hazardous consequences of various chemical compounds on humans drives the market's expansion. North America is the highest category spender by region, driving the demand for the In-Vivo Toxicology Testing industry.

Industry Definition and Segmentation

In Vivo, Toxicology refers to scientific research conducted within an intact, live creature, such as a laboratory animal, to better understand the hazardous consequences of various chemical compounds supplied to the test subject. These tests can also check that the medicine or substance of choice is free of dangerous substances. In-vivo testing is used in preclinical studies. The In-Vivo Toxicology Testing industry report comprises segments by end-use (pharmaceuticals, chemical and agrochemicals) and region (North America, Europe, Asia Pacific, the Middle East, Africa, and Latin America).

The North American Region is Driving the Growth of the Industry

North America holds the largest share in the industry, which comprises the United States and Canada. Because of its technological superiority and the presence of significant firms, the region is dominating the industry. In addition, the presence of key players operating in the in vivo toxicology market and expanding biomedical research in the United States and rising preclinical activities by CROs and pharmaceutical firms in the region account for the region's prominent position.

The changing dynamics are driving the market in the global healthcare market, which has driven pharmaceutical and biotechnology businesses to create treatments that provide substantial value rather than merely incremental improvements. As a result, many pharmaceutical and medical device companies focus on newer innovations and improving their R&D efficiency. The pharmaceutical market will benefit from increased demand for innovative therapies, which will feed a need for clinical studies of new drug candidates. In addition, the growing popularity of humanised animal models, which are valuable tools for doing preclinical research and learning more about human biology, is further boosting industry growth. The desire to understand how medications affect people and an increasing interest in researching human-specific infections, treatments and immunological responses drive the development and usage of humanised animal models. Also, the government's compulsory in-vivo testing will support the segment's growth in the future.

Best Procurement Practices

The global In-Vivo Toxicology Testing industry report by Procurement Resource gives an in-depth analysis of the best buying practices followed by major global In-Vivo Toxicology Testing regions, such as engagement models and contract terms, and buyer and supplier negotiation levers, among others.

Category Management Studies

Animal research and clinical trials are the two most common forms of in vivo tests. Researchers use animal studies to learn more about the mechanisms that underpin various disease processes and test new medicinal therapies' safety. The majority of animal research employs genetically identical laboratory-bred mice or rats. As a result, scientists can keep track of various biological impacts on complex organisms. Researchers test potential novel medicines or procedures in the lab and animals before moving them into human clinical trials. Clinical studies are divided into many stages. During an investigation, researchers learn more about the prospective therapy, its hazards, how it could or might not work, and quality of life aspects.

The Integration of Technological Advancements, Further Boosting the In-Vivo Toxicology Testing Market

The industry is witnessing development due to various technologies that provide alternatives to animal testing. Regulatory compliance also requires service providers to limit the number of in-vivo models by employing the 3R concept. CROs are increasingly utilising the 3R (Replace, Refine, and Reduce) to minimise the number of animals used in toxicological investigations. Pharmaceutical R&D efforts are expanding, as are animal model advances, the creation of exclusive in vivo toxicological testing, and the growing need for individualised treatment and innovative therapies.

However, the market may decline due to pressure from animal welfare groups like PETA. On the other hand, researchers and toxicologists are looking for alternatives to animal testing, likely to create new market opportunities.

The regional markets for the industry can be divided into North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.

Key Industry Players Mentioned in the In-Vivo Toxicology Testing Industry Report

• Charles River Laboratories International, Inc
• Labcorp Drug Development
• Eurofins Scientific, S.E.
• WuXi AppTec Co., Ltd.
• Creative Animodel

Market Landscape

Market participants use organic and inorganic tactics to enhance their market share and client base and solidify their market share. Because the amount of work is not huge and thus helps create a connection before participating in strategic collaboration, the majority of the suppliers (small Biotech) adopted the project by project approach. Strategic partnerships are becoming more popular.

Key Initiatives by Companies

• Covance announced the purchase of Envigo's non-clinical CRO services in June 2019. The firm increased its service offerings and enhanced its client base due to this purchase.